I suddenly remembered this stuff from a couple of years ago. Emapunil (XBD-173) was supposed to be the new benzodiazepine with no (benzodiazepines-like) side effects. Last thing I heard about it, is that the Japanese (Dainippon Sumitomo Pharma) bought the rights from the Novartis researchers who originally discovered the compound.
One clinical trial with 71 healthy male volunteers was done in 2009. Here is the study: http://www.ncbi.nlm....pubmed/19541954
Some more info about emapunil or XBD-173:
http://benzowithdraw...m/tag/emapunil/
http://www.ncbi.nlm....pubmed/21609361
Another promising anxiolytic is a selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH) such as URB597 (als known as KDS-4103).
Some info:
http://www.genome.du...easily-overcome
http://www.ncbi.nlm....pubmed/23333350
http://www.ncbi.nlm..../PMC3171696/#s1
The last link leads to a study wherein is suggested that FAAH inhibition leads to some form of cognitive impairement.
Since group buys are going good around here, I thought that one of these two compounds might be another candidate for another group buy. I am suggesting emapunil.
